This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Genmab Initiates DKK 725 Million...
Business share buy-back

Genmab Initiates DKK 725 Million Share Buy-Back

Analysis based on 14 articles · First reported Feb 17, 2026 · Last updated Mar 02, 2026

Sentiment
10
Attention
2
Articles
14
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The share buy-back program by Genmab is generally viewed positively by the market, as it can increase shareholder value and signal confidence from the company's management. The repurchase of shares reduces the number of outstanding shares, potentially boosting earnings per share and stock price for Genmab.

Biotechnology Pharmaceuticals
Event Summary

Genmab, an international biotechnology company, announced the initiation of a share buy-back program on February 17, 2026. The program aims to repurchase up to 342,130 shares, with a maximum aggregate value of DKK 725 million, to fulfill commitments under its Restricted Stock Unit program. The program is expected to conclude by March 31, 2026. Transactions under the program have been executed from February 18 to February 20, 2026, and from February 23 to February 27, 2026, with a total of DKK 271,855,470 accumulated under the program. Following these transactions, Genmab holds 2,763,851 shares as treasury shares, representing 4.30% of its total share capital and voting rights. The program adheres to Regulation (EU) No. 596/2014 ('MAR') and the Commission Delegated Regulation (EU) 2016/1052, also known as the 'Safe Harbour Regulation'.

Key Actions
100 Genmab initiated share buy-back program
90 Genmab repurchased shares
Entities Involved
stock
Genmab
Genmab initiated a share buy-back program to repurchase up to 342,130 shares with a maximum aggregate total value of DKK 725 million. This program is intended to honor commitments under its Restricted Stock Unit program, which generally has a positive impact on shareholder value and stock price.
Importance 100 Sentiment 20
curr
Denmark===Danish krone
The share buy-back program by Genmab is valued in Denmark===Danish krone, indicating the currency of transaction for the repurchase of shares.
Importance 10 Sentiment 0
exch
Nasdaq
Genmab is listed on Nasdaq, which is the exchange where its shares are traded and the buy-back program transactions are executed.
Importance 5 Sentiment 0
govactor
United States===United States Securities and Exchange Commission
Genmab's financial reports and risk factors are filed with the United States===United States Securities and Exchange Commission, indicating regulatory oversight for its public listings.
Importance 5 Sentiment 0
alliance
European Union
The share buy-back program by Genmab is undertaken in accordance with Regulation (EU) No. 596/2014 ('MAR') and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the 'Safe Harbour Regulation', which are European Union regulations.
Importance 5 Sentiment 0
Relationships
Genmab related ↔ United States===United States Securities and Exchange Commission
Genmab related ↔ European Union
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.